PARIS and SALT LAKE CITY, March 20, 2014 (GLOBE NEWSWIRE) -- Institut Pasteur and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics, Inc., today announced they have published an initial data analysis from the landmark Milieu Interieur Project in the journal Immunity, which provided new insights into the healthy human immune response. The Milieu Interieur project ( www.milieuinterieur.fr/en ) is a population-based study supported by the French National Ministry of Research and coordinated by the Institut Pasteur, Paris that will characterize the immune phenotypes of 1,000 healthy subjects. The results could lead to the development of novel diagnostics and companion diagnostics.
In the paper titled , "Functional Analysis using Standardized Whole Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli," the authors describe the use of Myriad RBM's TruCulture ® technology, a proprietary blood collection and culturing system, to characterize individual immune responses of 25 healthy people to medically relevant stimuli. Unlike the current laboratory-based methods, TruCulture is deployed at the site of collection and therefore avoids variability from shipping and complex processing as well as the expense of a cell culture facility and staff. The results in the Immunity paper show that TruCulture stimulations are reproducible, with close correspondence in repeated tests from the same subject.
"The immune system is highly complex and is responsible for maintaining healthy conditions in the body. Understanding responses to stimuli is critical to understanding the origins and progression of infection, autoimmunity and cancer," said Matthew Albert, co-coordinator of Milieu Interieur and director of the Immunology Department at Institut Pasteur. "As a clinical pathologist and immunologist, I believe it is important to have immune monitoring tools that reliably measure inflammatory responses and TruCulture performed exceedingly well. Our findings will lead to additional studies and possibly new diagnostic tests for inflammatory, autoimmune, oncological, and infectious diseases, as well as companion diagnostics for therapeutics."